Opko Health is a healthcare company. Co.'s segments are diagnostics and pharmaceutical. Co.'s diagnostics segment provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare. Co.'s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity.
